Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02271139
Title Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib
Recruitment No longer available
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Genentech, Inc.
Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST